Novartis’s drug Lutathera showed promise in a phase 3 trial for treating certain advanced gastroenteropancreatic neuroendocrine tumors, potentially opening up a $1 billion market as a first-line treatment. The drug and octreotide significantly reduced disease progression risks, increasing the median progression-free survival to almost 23 months compared to 8.5 months with the control. This could establish Lutathera as a standard initial treatment without needing additional FDA approval, as the company educates the medical community about the benefits.
To read more, click here.
[Source: Fierce Pharma, January 19th, 2024]